Compare KRNT & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRNT | STTK |
|---|---|---|
| Founded | 2002 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 668.4M | 538.3M |
| IPO Year | 2014 | 2020 |
| Metric | KRNT | STTK |
|---|---|---|
| Price | $14.34 | $6.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $19.75 | $10.00 |
| AVG Volume (30 Days) | 312.7K | ★ 522.7K |
| Earning Date | 05-13-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | $4.52 | N/A |
| Revenue Next Year | $7.84 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.93 | $0.71 |
| 52 Week High | $23.32 | $8.33 |
| Indicator | KRNT | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 35.86 | 42.55 |
| Support Level | $14.33 | $5.85 |
| Resistance Level | $14.99 | $6.81 |
| Average True Range (ATR) | 0.97 | 0.52 |
| MACD | -0.25 | -0.12 |
| Stochastic Oscillator | 5.64 | 23.03 |
Kornit Digital Ltd develops, designs and markets digital printing solutions for the world-wide printed textile industry. The company focuses on its DTG and DTF segments of the printed textile industry. Its solutions include digital printing systems, ink and other consumables, associated software and value-added services that allow for large-scale printing of short runs of complex images and designs directly on finished garments and fabrics. It generates revenue from sales of systems, ink and other consumables and service including software subscriptions The company geographically operates in U.S., EMEA, Asia Pacific and other countries. It derives maximum revenue from U.S.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.